ArGEN-X opens antibody r&d facility in Flanders
ArGEN-X, a Dutch biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary Simple Antibody technology, has opened an r&d subsidiary in Flanders.
ArGEN-X, a Dutch biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary Simple Antibody technology, has opened an r&d subsidiary in Flanders.
The facility is supported by a Euro 1.3m grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). The company plans for it to become a centre of excellence for the discovery and development of novel therapeutic antibodies.
The facility will be managed by ArGEN-X" chief scientific officer Dr Hans de Haard and chief development officer Dr Torsten Dreier. Eventually a team of 25 antibody scientists will be based at the new facility.
"We have chosen to locate our r&d facility in what is the heart of the Benelux Biotech cluster and in a region with well-established infrastructure and expertise from which ArGEN-X can draw," said de Haard.
"We are confident that we can create a centre of excellence in Flanders, which will serve as a magnet to some of the best antibody talents globally."
